Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference19 articles.
1. Has the time come to abandon efavirenz for first-line antiretroviral therapy?;Raffi;J Antimicrob Chemother,2014
2. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?;Vitoria;AIDS,2018
3. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study;O’Connor;Lancet HIV,2017
4. Cohort profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord;Chêne;Int J Epidemiol,2017
5. Understanding competing risks: a simulation point of view;Allignol;BMC Med Res Methodol,2011
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long-term efavirenz exposure induced neuroinflammation and cognitive deficits in C57BL/6 mice;Biochemical and Biophysical Research Communications;2021-12
2. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study;BMC Infectious Diseases;2021-01-23
3. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial);PharmacoEconomics;2020-12-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3